Table 8.
Selected clinical trials that incorporate CAR T-cell products in experimental therapy of NHL.
| Drug Combination | Mode of Action | Study Phase | Disease Status | Estimated Study Completion Date | ClinicalTrials.gov Identifier (Other Identifier) |
|---|---|---|---|---|---|
| Axi-cel | Anti-CD19 CAR T-cells versus ASCT (2nd line therapy) | 3 | R/R hgB-NHL | January 2022 | NCT03391466 (ZUMA-7) |
| Liso-cel | Anti-CD19 CAR T-cells versus ASCT (2nd line therapy) | 3 | R/R hgB-NHL | January 2024 | NCT03575351 (TRANSFORM) |
| Tisa-cel | Anti-CD19 CAR T-cells versus ASCT (2nd line therapy) | 3 | R/R hgB-NHL | December 2025 | NCT03570892 (BELINDA) |
| Axi-cel | Anti-CD19 CAR T-cells | 2 | R/R FL, R/R MZL | February 2022 | NCT03105336 (ZUMA-5) |
| Liso-cel | Anti-CD19 CAR T-cells | 2 | R/R B-NHL ineligible for ASCT | April 2021 | NCT03483103 (TRANSCEND-PILOT-017006) |
| KTE-X19 | Anti-CD19 CAR T-cells | 1 | R/R SLL/CLL | August 2021 | NCT03624036 |
| Liso-cel + ibrutinib | Anti-CD19 CAR T-cells + BTK inhibitor ibrutinib | 1/2 | R/R CLL/SLL | October 2021 | NCT03331198 |
| Axi-cel + acalabrutinib | BTK inhibitor acalabrutinib administered before leukapheresis | 1/2 | R/R hgB-NHL | March 2024 | NCT04257578 |
| CD30.CAR T cells | Anti-CD30 CAR T-cells | 1 | R/R HL, CD30+ NHL | April 2021 | NCT02917083 (RELY-30) |
| AUTO4 | Anti-TRBC1 CAR T-cells | 1/2 | R/R T-NHL | July 2021 | NCT03590574 |
| CD4CAR | Anti-CD4 CAR T-cells | 1 | R/R T-NHL | December 2022 | NCT03829540 |
| Axi-cel | Anti-CD19 CAR T-cells | 1 | DLBCL (PET+ after 2 cycles of therapy) | June 2021 | NCT03761056 (ZUMA-12) |
| ALTCAR.CD30 | ASCT followed by anti-CD30 CAR T-cells | 1 | R/R HL, CD30+ NHL | September 2021 | NCT02663297 |
| AlloSCT + CAR-T | T-cell depleted alloSCT + donor anti-CD19 CAR T-cell-based consolidation | 1 | B-ALL, CLL, NHL | September 2023 | NCT04556266 |
| CAR 20/19 | Bispecific anti-CD20/anti-CD19 CAR T-cells | 1/2 | R/R B-NHL | May 2023 | NCT04186520 |
| Liso-cel + avadomide, iberdomide, ibrutinib, or durvalumab | Anti-CD19 CAR T-cells in combination with immunomodulatory drugs avadomide/iberdomide, BTK inhibitor ibrutinib or anti PD-L1 checkpoint durvalumab | 1/2 | R/R hgB-NHL | August 2023 | NCT03310619 (PLATFORM) |
| AUTO3 + pembrolizumab | Dual anti-CD19/anti-CD22 CAR T-cells + anti PD-1 immune checkpoint inhibitor pembrolizumab | 1/2 | R/R hgB-NHL | March 2021 | NCT03287817 (ALEXANDER) |
| CD19-PD1-CART | Anti-CD19 CAR T-cells with PD-1/CD28 co-stimulation | 1 | R/R B-NHL | July 2021 | NCT04163302 |
| CD7.CAR | Anti-CD7 CAR T-cells with CD7 deletion | 1 | R/R CD7+ T-cell malignancies | May 2023 | NCT03690011 (CRIMSON) |
| iC9/CAR.19/IL15-Transduced CB-NK Cells | Cord blood-derived allogeneic anti-CD19 NK-cells with IL-15 and inducible caspase 9 | 1/2 | B-ALL, CLL, B-NHL | June 2022 | NCT03056339 |
| CD19.CAR-aNKT | Anti-CD19 allo CAR NK/T cells with IL-15 | 1 | R/R ALL, CLL, hgB-NHL | April 2023 | NCT03774654 |
Abbreviations: alloSCT= allogeneic stem cell transplantation; ASCT= autologous stem cell transplantation; B-ALL= B-cell acute lymphoblastic leukemia; BTK= Bruton tyrosine-kinase inhibitor; CLL/SLL= chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL= diffuse large B-cell lymphoma; FL= follicular lymphoma; hgB-NHL= high-grade B-NHL; HL= Hodgkin lymphoma; HSCT= hematopoietic stem cell transplantation; iC9= inducible caspase 9; MZL= marginal zone lymphoma; R/R= relapsed/refractory; NHL= non-Hodgkin lymphomas.